Related Experiment Videos
The challenge of risk reduction therapy for cardiovascular disease
1Division of Cardiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill 27599-7075, USA.
Insights
Implementing risk reduction therapies significantly benefits cardiovascular disease patients by improving survival and quality of life. Enhanced care management is recommended for wider adoption of these life-saving strategies.
Area of Science:
- Cardiology
- Preventive Medicine
- Health Services Research
Background:
- Coronary heart disease management traditionally focused on interventions like angioplasty and bypass surgery.
- Emerging evidence highlights the critical role of medical risk reduction therapies.
Purpose of the Study:
- To emphasize the benefits of risk reduction therapies for cardiovascular disease patients.
- To advocate for systemic changes in healthcare delivery to improve the implementation of these therapies.
Main Methods:
- Review of randomized clinical trials demonstrating the efficacy of risk reduction therapies.
- Consensus recommendations from the American Heart Association on therapy implementation.
- Proposal for risk reduction case management by nursing staff.
Main Results:
- Risk reduction therapies significantly extend survival and improve quality of life.
- These therapies decrease the need for procedures like angioplasty and bypass grafting.
- Reduced incidence of subsequent myocardial infarction is a key outcome.
Conclusions:
- Risk reduction therapies are crucial for cardiovascular disease patients, offering substantial survival and quality-of-life benefits.
- Current adoption rates are suboptimal, necessitating changes in healthcare delivery systems.
- Risk reduction case management and insurer support are vital for routine implementation.
Abstract:
Patients with cardiovascular disease can derive significant benefit from the implementation of risk reduction therapies. Until recently, management of patients with coronary heart disease has centered on the use of angioplasty, bypass surgery and medical therapy for severe fixed obstructions. Several large randomized clinical trials now demonstrate the importance of medical risk reduction therapies in these patients. A consensus panel of the American Heart Association recommends that health care providers use a group of risk reduction therapies, which can significantly extend overall survival, improve quality of life, decrease the need for interventional procedures such as angioplasty and bypass grafting, and reduce the incidence of subsequent myocardial infarction. Since a minority of patients with cardiovascular disease now benefit from these strategies, changes in our health care delivery systems are recommended. Risk reduction case management by nursing staff can assist physicians and improve implementation of and patient adherence to these therapies. Programs are being discussed to develop support by third-party insurers for risk reduction therapies. Application of these therapies should be a routine part of care for patients with cardiovascular disease.